Physician profile
Dany A Obeid
NPI 1841336310
$163,307.59
in general payments reported to CMS, 2019-2025
51 companies · $4,011 in 2025
The $4,011 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $33K · 2021: $29K · 2022: $33K · 2023: $29K · 2024: $2,422 · 2025: $4,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $7,159 · Education: $3,190 · Travel and Lodging: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,725.00 |
| Food and Beverage | $7,159.23 |
| Education | $3,189.91 |
| Travel and Lodging | $1,419.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $147,788.26 | 2019-2025 | Nucala, Trelegy Ellipta |
| Intuitive Surgical, INC. | $3,432.43 | 2023 | Ion, Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,292.81 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,278.87 | 2019-2025 | Tezspire, Breztri, Farxiga |
| Olympus Corporation of The Americas | $1,003.56 | 2025 | |
| Jazz Pharmaceuticals INC. | $948.60 | 2021-2025 | Xywav |
| Grifols USA, LLC | $867.20 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $835.43 | 2021-2025 | Glassia |
| Genzyme Corporation | $729.93 | 2019-2025 | |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Inspire Medical Systems, INC. | $412.01 | 2023-2025 | Inspire |
| Amgen INC. | $362.72 | 2019-2025 | Tezspire |
| Harmony Biosciences LLC | $352.37 | 2020-2025 | |
| Electromed, INC. | $332.34 | 2019-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $300.68 | 2019-2025 | Dupixent |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $279.62 | 2023-2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $268.59 | 2021-2025 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Baxter Healthcare | $235.94 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Ani Pharmaceuticals, INC. | $187.81 | 2023-2025 | Purified Cortrophin Gel |
| Philips North America LLC | $166.14 | 2022-2024 | (Ak6) Vest Therapy, (8874) Incourage |
| Mallinckrodt Hospital Products INC. | $136.79 | 2022-2025 | Acthar |
| Genentech USA, INC. | $136.47 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $129.57 | 2020-2025 | Uptravi, Opsumit |
| Inogen, INC. | $117.55 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Avadel Cns Pharmaceuticals, LLC | $107.73 | 2024-2025 | Lumryz |
| Axsome Therapeutics, INC. | $98.48 | 2023-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $95.63 | 2023-2025 | Winrevair, Keytruda |
| Mylan Specialty L.P. | $93.29 | 2019-2024 | Yupelri |
| Viatris Specialty LLC | $92.60 | 2025 | Yupelri |
| Circassia INC. | $65.63 | 2019 | |
| Shire North American Group INC | $50.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $50.51 | 2019-2020 | |
| Vifor Pharma, INC. | $49.42 | 2025 | Zemaira |
| Teva Pharmaceuticals USA, INC. | $48.44 | 2019-2022 | |
| Zoll Respicardia, INC. | $43.85 | 2023-2025 | Remede System |
| Fisher & Paykel Healthcare INC | $40.32 | 2023-2025 | Fisher & Paykel Healthcare |
| Lilly USA, LLC | $39.73 | 2025 | Zepbound |
| Alk-Abello, INC | $34.84 | 2024-2025 | Ragwitek, Odactra, Grastek |
| Genentech, INC. | $31.93 | 2022 | |
| Medtronic, INC. | $26.06 | 2022 | |
| Novo Nordisk INC | $25.08 | 2025 | Wegovy |
| Pfizer INC. | $24.74 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.14 | 2019 | |
| Allergan, INC. | $17.49 | 2019 | |
| Nabriva Therapeutics, Plc | $17.48 | 2020 | |
| Verona Pharma, INC. | $13.79 | 2025 | Ohtuvayre |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dany Obeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.